PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
131.08%
Revenue growth above 1.5x RUN's 12.90%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
51.20%
Positive gross profit growth while RUN is negative. John Neff would see a clear operational edge over the competitor.
No Data
No Data available this quarter, please select a different quarter.
55.54%
Operating income growth above 1.5x RUN's 0.47%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
14.86%
Net income growth under 50% of RUN's 460.66%. Michael Burry would suspect the firm is falling well behind a key competitor.
-1378.57%
Negative EPS growth while RUN is at 456.14%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-1378.57%
Negative diluted EPS growth while RUN is at 436.85%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-94.15%
Share reduction while RUN is at 1.22%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-94.15%
Reduced diluted shares while RUN is at 1.26%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-1171.14%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-60.97%
Negative FCF growth while RUN is at 156.78%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.32%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
No Data
No Data available this quarter, please select a different quarter.